Meetings 

Meda is a global specialty pharma company with products in over 120 countries worldwide and $1.9BUSD in sales.

Meda's primary growth strategy is search and acquire focusing on acquisitions aligned with our current verticals (allergy/respiratory; women and men's health; dermatology (EU); cardiovascular (EU); and pain and inflammation).

We tend towards low risk investments, hence, late stage products (e.g., successful completion of a Phase III) or marketed products. We avoid 505(b)(2) products unless there is a clear unmet need that is met by a highly differentiated product.

Metanomics Health, a BASF group company, is the world leading company offering targeted and non-targeted metabolite profiling to healthcare customers in industry and academia. We serve pharma, nutrition and diagnostics customers, making them more successful through biomarker identification and validation across a broad range of applications.

In parallel to our third party service business we are funding and conducting a comprehensive diagnostic biomarker program in the areas of cardio-metabolic diseases, multiple sclerosis and various oncology indications, addressing open questions of high and unmet medical need.

Biomarkers covering disease diagnosis, mechanism of drug toxicity, mechanism of action and drug efficacy are increasingly needed in the preclinical and clinical setting for better evaluation of novel chemical entities including target validation and tailor-made treatment regimens.

Our non-biased broad profiling platform as well as the hypothesis-driven targeted metabolomics platforms have the potential for providing novel biomarkers of disease and drug efficacy and are routinely incorporated into biomarker discovery and validation studies.

We enhance contextualization of our reproducible and robust metabolic signatures via integration with data from other “-omics” platforms such as transcriptomics or proteomics. In our systems biology approach we are linking known metabolites and genes to relevant pathways and phenotypes, i.e. mapping genotype to phenotype.

Our customers´ personalized medicines and nutrition solutions are guided by differentiated and robust metabolite biomarker signatures, thus making sure that the right intervention is selected for the right person at the right time.

NanoSmart has developed and patented, a targeted drug delivery platform using human-derived, autoimmune antibodies capable of targeting many different kinds of tumors.  NanoSmart’s antitumor antibody, is not tumor-marker specific, but rather targets the areas of necrosis present in all solid tumors; including breast, lung, prostate, and rare cancers like Ewing’s Sarcoma.  Normal tissues do not have areas of necrosis and are not targeted.

NanoSmart is encapsulating off-patent FDA-approved drugs within liposomes coated with NanoSmart’s human-derived antibodies, thus creating an immunoliposome.  The liposome that encloses the active pharmaceutical ingredient protects healthy tissues while traveling to its target, and then slowly releases the drug over time.  NanoSmart’s antibody will then bind to the necrotic areas present in the middle of solid tumors and at the surrounding tumor site.

The end-result of using NanoSmart’s platform is a superior safety and efficacy profile for any drug that is adapted to our system.  Many different formulations can be developed by simply replacing one drug with another.  Each formulation is novel, patentable, and non-tumor specific (i.e. targets multiple cancers), and can be developed at a fraction of the cost and time typically associated with new drug development (i.e. IND to NDA in approximately 2-3 years).

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar is well-respected as a partner-of-choice with the world's leading pharmaceutical and biotechnology companies. Our platform technologies are validated and used in many of today's top-selling commercial drugs. As a result, industry returns to us time and time again to co-develop the next-generation of successful drugs designed to meet critical unmet medical needs.

Our strategic partnerships range from joint discovery and co-development to licensing and royalty arrangements with a wide range of organizations.

Novartis Oncology profile

 A business unit within the Novartis Group, Novartis Oncology delivers a broad range of innovative therapies and practical solutions that help change the way patients live with cancer and blood disorders. Glivec® (imatinib) is an oral treatment for multiple rare diseases including forms of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) and Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Tasigna® (nilotinib) is approved for Ph+ CML adult patients resistant to or intolerant to at least one prior therapy. Afinitor® (everolimus) is indicated for patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy. Zometa® (zoledronic acid) is indicated for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Zometa also treats hypercalcemia of malignancy. Femara® (letrozole) is approved for adjuvant treatment of hormone receptor positive early breast cancer as well as for extended adjuvant treatment of hormone receptor positive early breast cancer after five years of initial tamoxifen therapy. It is also approved for several uses in certain postmenopausal women with advanced breast cancer. Sandostatin® LAR® (octreotide) helps control symptoms, such as severe diarrhea and flushing, associated with functional gastroenteropancreatic neuroendocrine tumors. It is also approved for the treatment of acromegaly. Exjade® (deferasirox) is approved to treat iron overload in a broad range of patients receiving ongoing blood transfusions. Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Partnering strategy

Novartis Oncology is seeking to license or acquire targeted therapeutic approaches to cancer treatment, with a particular interest in projects that have demonstrated Proof-of-Concept in human trials.